Completed PHASE2 INTERVENTIONAL 2-arm NCT01695343

Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment (KB001-A)

A Phase 2, Randomized, Double-blind, Placebo-controlled, Repeat-dose Study of KB001-A in Subjects With Cystic Fibrosis Infected With Pseudomonas Aeruginosa

Sponsor: Humanigen, Inc.

Conditions Cystic Fibrosis

Interventions KB001-A Placebo Comparator

Updated 8 times since 2017 Last updated: Jan 12, 2015 Started: Dec 31, 2012 Primary completion: Nov 30, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Cystic Fibrosis, this trial is completed. The trial is conducted by Humanigen, Inc. and has accumulated 8 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Apr 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Humanigen, Inc.

Data source: Humanigen, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Albuquerque, United States , Atlanta, United States , Aurora, United States , Austin, United States , Boise, United States , Boston, United States , Charleston, United States , Cincinnati, United States , Cleveland, United States and 54 more locations